Drug intelligence / Profile preview

NAL9407

Development stage: Preclinical
Lead developer: Nal Pharmaceuticals
Modality: Drug Delivery Systems
Administration: Intravenous, Parenteral

Overview

NAL9407 is a proposed **intravenous parenteral-nutrition formulation** from NAL Pharma. The company describes it as a fixed multi-compartment nutritional product containing a fat emulsion, 16 amino acids, and 36% glucose, intended to provide intravenous macronutrient support when parenteral nutrition is required. NAL Pharma lists the product under proposed United States ANDA filings. ([nalpharma.com](https://nalpharma.com/licensing.php))

Beyond the preview

Go deeper on NAL9407.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAL9407.

Explore the full profile